Advanced search
Publication Cover
Clinical Ophthalmology Volume 13, 2019 - Issue
Submit an article Journal homepage
172
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial

Rodrigo A Brant Fernandes1 Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo, SP, Brazil
,
Luci Meire P Silva1 Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo, SP, Brazil
,
Diego Torres Dias1 Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo, SP, Brazil
,
Rafael Henrique Pereira2 IPEPO/Vision Institute – SP, São Paulo, SP, Brazil
,
Rubens Belfort Jr1 Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo, SP, Brazil;2 IPEPO/Vision Institute – SP, São Paulo, SP, Brazil
&
Tiago Santos Prata1 Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo, SP, Brazil;2 IPEPO/Vision Institute – SP, São Paulo, SP, Brazil;3 Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USACorrespondence[email protected]
Pages 679-684 | Published online: 24 Apr 2019

References

  • Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711–1720. doi:10.1016/S0140-6736(04)16257-0
  • Kingman S. Glaucoma is second leading cause of blindness globally. Bulletin of the World Health Organization. 2004;82(11):887–888.
  • Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013
  • Prum BE Jr., Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern((R)) guidelines. Ophthalmology. 2016;123(1):P41–P111. doi:10.1016/j.ophtha.2015.10.053
  • Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opinion on Pharmacotherapy. 2007;8(18):3237–3249. doi:10.1517/14656566.8.18.3237
  • van der Valk R, Schouten JS, Webers CA, et al. The impact of a nationwide introduction of new drugs and a treatment protocol for glaucoma on the number of glaucoma surgeries. Journal of Glaucoma. 2005;14(3):239–242.
  • Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. Journal of Glaucoma. 2008;17(8):667–673. doi:10.1097/IJG.0b013e3181666557
  • Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100(9):1297–1304.
  • Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Archives of Ophthalmology. 1993;111(10):1351–1358.
  • Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103(1):138–147. doi:10.1016/S0161-6420(96)30749-5
  • Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Investigative Ophthalmology & Visual Science. 2000;41(9):2566–2573.
  • Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113(2):239–246. doi:10.1016/j.ophtha.2005.10.045
  • Zore M, Harris A, Tobe LA, et al. Generic medications in ophthalmology. The British Journal of Ophthalmology. 2013;97(3):253–257. doi:10.1136/bjophthalmol-2012-302245
  • Digiuni M, Manni G, Vetrugno M, et al. An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension. Journal of Glaucoma. 2013;22(9):707–712. doi:10.1097/IJG.0b013e318259b47c
  • Chambers WA. Ophthalmic generics–are they really the same? Ophthalmology. 2012;119(6):1095–1096. doi:10.1016/j.ophtha.2012.03.033
  • Angmo D, Wadhwani M, Velpandian T, Kotnal A, Sihota R, Dada T. Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations. International Ophthalmology. 2017;37(2):423–428. doi:10.1007/s10792-016-0280-x
  • Cantor LB. Ophthalmic generic drug approval process: implications for efficacy and safety. Journal of Glaucoma. 1997;6(5):344–349. doi:10.1097/00061198-199710000-00011
  • Golan S, Rosenfeld E, Shemesh G, Kurtz S. Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: are they really the same? Clinical and Experimental Pharmacology & Physiology. 2015;42(2):220–224. doi:10.1111/1440-1681.12329
  • Narayanaswamy A, Neog A, Baskaran M, et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian Journal of Ophthalmology. 2007;55(2):127–131. doi:10.4103/0301-4738.30707
  • Diagourtas A, Kagelaris K, Oikonomakis K, Droulias A, Kokolakis N, Papaconstantinou D. Prospective study comparing Xalatan((R)) eye drops and two similar generics as to the efficacy and safety profile. European Journal of Ophthalmology. 2018;28(4):378–384. doi:10.1177/1120672117747030
  • Allaire C, Dietrich A, Allmeier H, et al. Latanoprost 0.005% test formulation is as effective as Xalatan(R) in patients with ocular hypertension and primary open-angle glaucoma. European Journal of Ophthalmology. 2012;22(1):19–27. doi:10.5301/ejo.5000041

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.